Imaging for Oncologic Response Assessment in Lymphoma

Area of Science:

• Oncology
• Radiology
• Medical Imaging

Background:

• Lymphoma and metastatic solid tumors frequently involve lymph nodes.
• Advances in cancer therapy for lymphoma and metastases have improved patient outcomes.
• Imaging serves as a surrogate endpoint for monitoring treatment effects based on tumor bulk changes.

Purpose of the Study:

• To examine the role of various imaging biomarkers in assessing oncologic treatment effectiveness for lymphoma.
• To focus on updated CT and PET response criteria.
• To discuss other functional imaging methods and their limitations.

Main Methods:

• Review of updated CT and PET response criteria.
• Exploration of molecular and functional imaging methods (PET, perfusion, DWI, dual-energy CT).
• Assessment of imaging biomarkers beyond tumor burden measurement.

Main Results:

• Established criteria based on tumor bulk changes are used to monitor treatment effects.
• Molecular and functional imaging methods are being investigated as biomarkers of response and prognosis.
• Advanced imaging biomarkers may offer early predictors of therapeutic response.

Conclusions:

• Evolving cancer therapies necessitate advanced imaging assessment beyond simple morphologic methods.
• Functional and molecular imaging hold potential for early prediction of therapeutic response in lymphoma.
• Challenges remain in the implementation and validation of these advanced imaging biomarkers.